Gyre Therapeutics, Inc. GYRE R2K

Healthcare · Biotechnology · United States

https://www.gyretx.com

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Market & Price

Market Cap

$573.44M

Current Price

$5.91

High / Low (52W)

$9.07 / $5.74

Beta

5.28

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

98.50

PEG Ratio

Book Value

$1.11

Price to Book

5.33

P/S

4.90

EV/EBITDA

103.82

Dividend Yield

Profitability & Returns

ROCE

7.77%

ROE

-3.08%

ROA

1.03%

Profit Margin

-5.44%

Op Margin

-30.21%

EPS (Latest Qtr)

$-0.10

EPS (TTM)

$-0.08

Balance Sheet & Liquidity

Debt/Equity

0.60

Quick Ratio

3.68

Current Ratio

4.64

Debt

$823.00K

Total Assets

$166.13M

Current Assets

$102.37M

Working Capital

$84.08M

Ownership

Promoter Holding

86.33%

Chg in Prom Hold

FII / Inst Holding

3.75%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$526.70M

Total Revenue (TTM)

$117.05M

EBITDA

$5.07M

Free Cash Flow

$9.60M

Operating Cash Flow

$4.32M

Shares Outstanding

97.03M

Gross Margin

95.09%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

4.46%

Profit 5Y

29.74%

Revenue (YoY)

2.10%

Earnings (YoY)

PROS

Profit CAGR of 29.7% over 5 years.
Generates positive free cash flow.

CONS

Trading 34.8% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	GYRE Gyre Therapeutics, Inc. R2K	5.91	-	$573.44M	-	7.77%	-3.08%	4.46%	29.74%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2014	Sep 2014	Dec 2014	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	111.00K	318.00K	6.00K	-	-	-	-	-	16.37M	1.66M	893.00K	1.47M	1.13M	2.30M	794.00K	-	-	24.93M	29.33M	32.04M	27.17M	25.23M	-	-	22.06M	26.77M	30.56M	37.20M	22.52M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	894.00K	1.15M	1.63M	1.74M	1.23M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23.81M	28.25M	30.86M	26.19M	24.45M	-	-	21.16M	25.62M	28.94M	35.45M	21.29M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	18.89M	23.45M	22.01M	35.33M	28.09M
Operating Income	-2.21M	-1.64M	-1.80M	-3.03M	-2.20M	-3.88M	-4.68M	-4.57M	-4.92M	-5.71M	-4.17M	-5.94M	-5.88M	-6.68M	-7.11M	-8.35M	-15.71M	-14.38M	-13.20M	-5.07M	-17.36M	-16.10M	-22.44M	-19.91M	-25.23M	-14.70M	51.53M	-5.17M	6.66M	4.97M	12.76M	8.07M	3.19M	-	-	2.27M	2.17M	6.93M	120.00K	-6.80M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.81M	2.81M	7.58M	815.00K	-6.13M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.63M	2.24M	7.63M	-66.00K	-9.24M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	901.00K	662.00K	1.69M	1.30M	621.00K
Net Income	-2.08M	-1.50M	-1.30M	-2.86M	-1.72M	-5.05M	-5.13M	-3.59M	-4.83M	-4.77M	-4.14M	-5.88M	-5.79M	-5.04M	-6.48M	-7.69M	-15.08M	-13.78M	-12.71M	-4.05M	-17.25M	-16.03M	-22.44M	-19.93M	-25.24M	-14.54M	51.63M	-4.88M	4.22M	3.77M	7.51M	9.94M	4.54M	-	-	2.70M	442.00K	3.61M	-1.72M	-8.69M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.64	-0.80	-0.46	1.64	-0.16	0.03	0.02	0.05	0.03	0.01	-	-	0.00	0.00	0.03	-0.02	-0.10
R&D Expense	5.41M	1.34M	-	1.38M	1.32M	1.49M	-	2.29M	2.75M	3.40M	2.06M	3.40M	3.81M	3.77M	3.89M	5.58M	12.03M	11.11M	9.93M	13.26M	12.91M	12.25M	17.01M	15.39M	20.35M	9.70M	1.87M	803.00K	2.63M	3.57M	3.01M	2.18M	3.35M	2.77M	-	3.10M	3.42M	2.36M	-	6.74M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	1.02M	6.00K	-	20.95M	-	102.29M	113.45M	105.76M	116.59M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	4.79M	4.64M	3.88M	5.42M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	97.50M	108.81M	101.87M	111.17M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	88.29M	89.60M	85.64M	99.68M
Operating Income	-40.33M	13.12M	-9.74M	-8.14M	-10.12M	-7.51M	-13.80M	-20.42M	-21.82M	-33.82M	-57.28M	-57.37M	-	9.20M	19.21M	16.23M	11.49M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	10.33M	20.33M	17.82M	14.01M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	122.37K	43.34K	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	9.41M	-76.97M	23.22M	14.44M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	5.10M	8.52M	5.32M	4.56M
Net Income	-39.40M	10.90M	-8.53M	-7.00M	-9.97M	-6.61M	-14.76M	-16.95M	-21.56M	-30.05M	-55.18M	-56.24M	-	2.30M	-92.93M	12.09M	5.03M
Diluted EPS	-1.54	0.36	-0.27	-0.21	-	-	-	-	-	-	-	-	-	0.03	-1.41	0.05	0.02
R&D Expense	40.18M	64.55M	95.22M	49.09M	6.56M	5.27M	5.96M	11.55M	12.85M	21.47M	43.86M	52.98M	68.89M	-	13.78M	12.02M	13.70M

Compounded Sales Growth

5 Years:	4.46%
1 Year:	2.10%

Compounded Profit Growth

5 Years:	29.74%
1 Year:	-

Stock Price Performance

1 Year:	-34.84%
6 Months:	-23.45%
3 Months:	-28.28%
1 Month:	-19.59%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	262.79M	258.13M	189.58M	145.87M	2.98M	69.52M	38.09M	39.51M	124.92M	98.55M	94.85M	-	84.75M	116.54M	125.41M	166.13M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	49.65M	57.22M	64.79M	102.37M
Cash & Equivalents	51.20M	83.91M	165.85M	107.28M	3.40M	2.83M	1.54M	29.10M	10.26M	14.47M	31.21M	15.37M	30.36M	-	25.18M	33.51M	11.81M	37.07M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.12M	4.28M	6.34M	10.17M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15.74M	15.16M	19.59M	31.08M
Total Liabilities	-	-	170.94M	83.84M	13.66M	11.26M	3.46M	38.10M	22.02M	8.74M	4.97M	30.22M	18.78M	-	12.54M	102.59M	27.00M	23.85M
Current Liabilities	-	-	98.66M	78.61M	11.35M	10.98M	2.34M	37.76M	21.96M	8.74M	4.80M	28.90M	17.80M	-	12.24M	20.05M	19.52M	18.29M
Long Term Debt	-	-	1.35M	1.99M	1.14M	283.00K	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	613.00K	409.00K	1.60M	939.00K
Total Equity	57.37M	68.99M	91.85M	174.29M	-93.34M	-103.01M	-109.35M	31.43M	16.07M	30.77M	119.94M	68.34M	76.07M	-	42.52M	-15.83M	63.32M	106.03M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	76.58M	76.60M	86.31M	91.31M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-24.27M	138.30M	-83.72M	-64.24M	-40.61M	-	-	-	-19.94M	-28.55M	-43.61M	-55.05M	-	10.68M	25.89M	-3.64M	1.01M
Investing Cash Flow	9.80M	-62.80M	-57.67M	39.82M	13.41M	-	-	-	-11.20M	-71.32M	27.39M	9.66M	-	-13.81M	-19.76M	-19.88M	-474.00K
Financing Cash Flow	47.18M	6.45M	82.81M	-626.00K	-552.00K	-	-	-	21.08M	111.33M	327.00K	60.38M	-	0	2.50M	2.10M	24.38M
Capital Expenditure	-200.00K	-3.31M	-1.43M	-333.00K	-41.00K	-4.00K	-272.00K	-468.00K	-23.00K	-376.00K	-64.00K	-	-	-5.00M	-8.59M	-3.13M	-1.92M
Free Cash Flow	-24.47M	134.99M	-85.15M	-64.57M	-40.65M	-	-	-	-19.96M	-28.93M	-43.68M	-	-	5.68M	17.31M	-6.77M	-913.00K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-3.14M	8.63M	-21.42M	24.91M
Share Buybacks	-	-	-	-	-	-	82.00K	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-	-	-	-	-	-	-	-	-	-	-	-	-	45.03M	-	-	-

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	95.3%	95.9%	96.3%	95.4%
Operating Margin %	-	-	-	-	-	-	-	-	-2,143.6%	-563,700.0%	-	-273.9%	-	9.0%	16.9%	15.3%	9.9%
Net Margin %	-	-	-	-	-	-	-	-	-2,118.0%	-500,916.7%	-	-268.5%	-	2.3%	-81.9%	11.4%	4.3%
ROE %	-57.1%	11.9%	-4.9%	7.5%	9.7%	6.0%	-47.0%	-105.4%	-70.1%	-25.1%	-80.7%	-73.9%	-	5.4%	587.1%	19.1%	4.7%
ROCE %	-	8.0%	-5.4%	-4.6%	-7.5%	-1,164.2%	-43.5%	-126.6%	-70.9%	-28.2%	-82.2%	-74.5%	-	12.7%	19.9%	15.3%	7.8%

Shareholding Pattern

Insiders

86.33%

Institutions

3.75%

Public Float

27.45%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Vanguard Capital Management LLC	1.01%	984.20K	$5.82M
2	Blackrock Inc.	0.78%	758.63K	$4.48M
3	Geode Capital Management, LLC	0.44%	431.41K	$2.55M
4	State Street Corporation	0.22%	216.33K	$1.28M
5	SBI Securities Co., Ltd.	0.18%	170.84K	$1.01M
6	Charles Schwab Investment Management, Inc.	0.17%	165.24K	$976.56K
7	Vanguard Fiduciary Trust Co	0.14%	137.68K	$813.70K
8	Northern Trust Corporation	0.14%	133.84K	$791.00K
9	Goldman Sachs Group Inc	0.08%	73.12K	$432.15K
10	Vanguard Portfolio Management LLC	0.07%	69.81K	$412.60K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GYRE

No recent headlines available.

GYRE · Healthcare